These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 6400672)

  • 21. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.
    Hansen HP; Rossing P; Tarnow L; Nielsen FS; Jensen BR; Parving HH
    Kidney Int; 1995 Jun; 47(6):1726-31. PubMed ID: 7643542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
    Tarnow L; Rossing P; Jensen C; Hansen BV; Parving HH
    Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.
    Mogensen CE
    Br Med J (Clin Res Ed); 1982 Sep; 285(6343):685-8. PubMed ID: 6809187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.
    Parving HH; Hommel E; Smidt UM
    BMJ; 1988 Oct; 297(6656):1086-91. PubMed ID: 3143437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension in diabetes as related to nephropathy. Early blood pressure changes.
    Feldt-Rasmussen B; Borch-Johnsen K; Mathiesen ER
    Hypertension; 1985; 7(6 Pt 2):II18-20. PubMed ID: 3878333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is antihypertensive treatment the same for NIDDM and IDDM patients?
    Parving HH
    Diabetes Res Clin Pract; 1998 Apr; 39 Suppl():S43-7. PubMed ID: 9649959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uncontrolled hypertension is associated with a rapid progression of nephropathy in type 2 diabetic patients with proteinuria and preserved renal function.
    Baba T; Murabayashi S; Tomiyama T; Takebe K
    Tohoku J Exp Med; 1990 Aug; 161(4):311-8. PubMed ID: 2256104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.
    Parving HH; Hommel E; Jensen BR; Hansen HP
    Kidney Int; 2001 Jul; 60(1):228-34. PubMed ID: 11422755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in albuminuria predicts diminished progression in diabetic nephropathy.
    Rossing P; Hommel E; Smidt UM; Parving HH
    Kidney Int Suppl; 1994 Feb; 45():S145-9. PubMed ID: 8158884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy.
    Mogensen CE; Christensen CK; Vittinghus E
    Diabetes; 1983 May; 32 Suppl 2():64-78. PubMed ID: 6400670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glomerular dysfunction in diabetic nephropathy.
    Zucchelli P; Zuccalà A; Sturani A
    Postgrad Med J; 1988; 64 Suppl 3():22-30; discussion 48-9. PubMed ID: 3074295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal function, glycemic control and perindopril in diabetic patients.
    Brichard S; Ketelslegers JM; Lambert AE
    Clin Exp Hypertens A; 1989; 11 Suppl 2():545-54. PubMed ID: 2691128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy.
    Mulec H; Blohmé G; Grände B; Björck S
    Nephrol Dial Transplant; 1998 Mar; 13(3):651-5. PubMed ID: 9550642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience.
    Parving HH; Rossing P; Hommel E; Smidt UM
    Am J Kidney Dis; 1995 Jul; 26(1):99-107. PubMed ID: 7611276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy.
    Passariello N; Sepe J; Marrazzo G; De Cicco A; Peluso A; Pisano MC; Sgambato S; Tesauro P; D'Onofrio F
    Diabetes Care; 1993 May; 16(5):789-95. PubMed ID: 8495620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal dose of losartan for renoprotection in diabetic nephropathy.
    Andersen S; Rossing P; Juhl TR; Deinum J; Parving HH
    Nephrol Dial Transplant; 2002 Aug; 17(8):1413-8. PubMed ID: 12147788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Gilbert RE; Hammond J; Cooper ME; Campbell DJ; Raffaele J
    J Diabetes Complications; 1995; 9(4):308-14. PubMed ID: 8573754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.
    Hansen HP; Nielsen FS; Rossing P; Jacobsen P; Jensen BR; Parving HH
    Kidney Int Suppl; 1997 Dec; 63():S49-53. PubMed ID: 9407421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.